17.02.2022 CompuGroup Medical SE & Co. KGaA  DE000A288904

DGAP-News: CompuGroup Medical USA delivers strong performance in 2021 after successful company integrations and growth in key areas


 

DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous
CompuGroup Medical USA delivers strong performance in 2021 after successful company integrations and growth in key areas

17.02.2022 / 15:08
The issuer is solely responsible for the content of this announcement.


  • Successful integration of eMEDIX EDI technology with over 80% of top resellers signed up to market the service
  • Strong growth in ARIA Health Service Revenue Cycle Management and Credentialing sales
  • New functionalities including telehealth and Remote Patient Monitoring released to the market
  • Accelerated and successful integrations of eMDs and Schuyler House businesses under a single CompuGroup Medical management team
  • Laboratory Information Systems group deploys key COVID reporting and verification functionality and experiences strong growth

Koblenz. CompuGroup Medical, Inc., the US division of CompuGroup Medical SE & Co. KGaA (CGM) reaffirmed its position as a market leader in the key US markets with a successful corporate integration and achievement of key goals in 2021. Following the late 2020 acquisitions and the full consolidation started on January 1st of the eMDs Electronic Health Records, Practice Management, and ARIA Revenue Cycle Management business; as well as that of Schuyler House Laboratory Information Systems, CGM achievements in 2021 demonstrate a successful year in the US.

The US Ambulatory Information Systems division also saw significant success. In additional to adding numerous new customers, releasing key upgrades, integrations of telehealth, remote patient monitoring and electronic data interchange services were released and cross-sold to clients across multiple software systems. CGM also delivered in the key e-prescribing data area. Patient and provider engagement functionality aimed at enhancing patient safety and improving quality provides key medication information to providers and patients, helps lower costs, and increases adherence to treatments.

The company saw significant growth in its ARIA revenue cycle management customer base. This was attributable to the increasing trend to outsource the medical billing process as well as a strong referral base. CGM US also saw over 80% of its key reseller distribution channel members agree to market CGM's eMEDIX EDI services. This channel is a key element of the company's strategy to reach more of the potential market for eMEDIX.

The Lab division completed the integration of Schuyler House 6 months earlier than planned. CompuGroup Medical lab division US now has the largest number of clients in the US independent lab market and had record sales of the LABDAQ and SCHUYLAB Laboratory Information Systems. CompuGroup Medical's lab division has also closed the acquisition of APEasy, a leading provider of anatomical pathology solutions which further complements the portfolio of lab solutions and adds an additional 700 customers. The combined CGM US business now accounts for more than 10% of CGM Group revenues.

"We are very proud of the achievements of every member of our team in 2021," said Derek Pickell, CEO, CompuGroup Medical US. "Over 60,000 providers and hundreds of thousands of users in our medical practices and enterprises, as well as laboratory customers have been so challenged by the COVID pandemic. More than ever, they have looked to their Health IT and services vendors as key partners to help them run healthy businesses so they can focus on healthy patients."

Dr. Dirk Wössner, Chief Executive Officer of CompuGroup Medical stated: "We have been so pleased with the work of the entire United States operation. From the rapid integration of the new businesses to the execution of numerous business plans under a single management team. The growth of the CGM brand in the United States has exceeded our expectations."

About CompuGroup Medical SE & Co. KGaA
CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 837 million in 2020, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists, and other healthcare professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. More than 8,500 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.

Contact for media representatives:
Alexander Weimer
Head of Brand Communication
P +49 261 8000-6100
E-mail: [email protected]

Contact for analysts and investors:
Claudia Thomé
Corporate Vice President Investor Relations
P +49 (0) 160 3630362
E-mail: [email protected]



17.02.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)261 8000 7030
Fax: +49 (0)261 8000 3200
E-mail: [email protected]
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1282527

 
End of News DGAP News Service

1282527  17.02.2022 

fncls.ssp?fn=show_t_gif&application_id=1282527&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 582,38 717,02 745,81 837,26 1.025,32 1.129,74 1.187,66
EBITDA1,2 128,44 187,84 178,13 197,48 213,39 216,35 229,76
EBITDA-Marge3 22,05 26,20 23,88 23,59 20,81 19,15
EBIT1,4 90,07 143,23 115,27 121,77 102,68 104,03 113,96
EBIT-Marge5 15,47 19,98 15,46 14,54 10,01 9,21 9,60
Jahresüberschuss1 31,74 96,34 66,15 73,42 69,03 74,12 46,87
Netto-Marge6 5,45 13,44 8,87 8,77 6,73 6,56 3,95
Cashflow1,7 85,82 136,35 110,50 149,93 165,27 145,03 179,53
Ergebnis je Aktie8 0,63 1,92 1,33 1,40 1,30 1,40 0,88
Dividende8 0,35 0,50 0,50 0,50 0,50 0,50 0,35
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
CompuGroup Medical
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A28890 29,320 Halten 1.575,50
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
22,55 35,87 0,62 25,17
KBV KCV KUV EV/EBITDA
2,56 8,78 1,33 9,81
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,50 1,00 3,41 22.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 08.08.2024 07.11.2024 28.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-6,73% -20,48% -22,64% -40,41%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu CompuGroup Medical SE & Co. KGaA  ISIN: DE000A288904 können Sie bei EQS abrufen


Software , A28890 , COP , XETR:COP